Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"

Affiliations

¹ Massachusetts General Hospital, Division of Hematology Oncology, 55 Fruit Street, Boston, MA 02114, USA.
² Weill Cornell Medicine Healthcare Policy and Research, 402 East 67th Street, LA-225, New York, NY 10065, USA.
³ The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 250 Lincoln Tower, Columbus, OH 43210, USA.
⁴ Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E. 66th Street, New York, NY 10065, USA.
⁵ University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Rm C-407 MIB/SPC 5843, Ann Arbor, MI 48109, USA.
⁶ Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, 450 Brookline Ave, D-1212, Brookline, MA 02215, USA.
⁷ Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
⁸ Ohio State University Wexner Medical Center, 410 West 10th Avenue, N924 Doan Hall, Columbus, OH 43206, USA.
⁹ Michigan Medicine, Department of Pathology, 1301 Catherine Street, SPC 5602, 3261G Medical Science I, Ann Arbor, MI 48109-5602, USA.
¹⁰ Cancer Research and Biostatistics, 1730 Minor Ave, Suite 1900, Seattle, WA 98101, USA.
¹¹ MD Anderson Cancer Center, Sarcoma Medical Oncology, 1400 Holcombe Blvd, Unit 450, Houston, TX 77030, USA.

Published Erratum

Edwin Choy et al. Sarcoma. 2019.

. 2019 Aug 27:2019:7608743.

doi: 10.1155/2019/7608743. eCollection 2019.

¹ Massachusetts General Hospital, Division of Hematology Oncology, 55 Fruit Street, Boston, MA 02114, USA.
² Weill Cornell Medicine Healthcare Policy and Research, 402 East 67th Street, LA-225, New York, NY 10065, USA.
³ The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 250 Lincoln Tower, Columbus, OH 43210, USA.
⁴ Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E. 66th Street, New York, NY 10065, USA.
⁵ University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Rm C-407 MIB/SPC 5843, Ann Arbor, MI 48109, USA.
⁶ Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, 450 Brookline Ave, D-1212, Brookline, MA 02215, USA.
⁷ Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
⁸ Ohio State University Wexner Medical Center, 410 West 10th Avenue, N924 Doan Hall, Columbus, OH 43206, USA.
⁹ Michigan Medicine, Department of Pathology, 1301 Catherine Street, SPC 5602, 3261G Medical Science I, Ann Arbor, MI 48109-5602, USA.
¹⁰ Cancer Research and Biostatistics, 1730 Minor Ave, Suite 1900, Seattle, WA 98101, USA.
¹¹ MD Anderson Cancer Center, Sarcoma Medical Oncology, 1400 Holcombe Blvd, Unit 450, Houston, TX 77030, USA.

Abstract

[This corrects the article DOI: 10.1155/2018/2068517.].

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.
Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. Choy E, et al. Sarcoma. 2018 Oct 24;2018:2068517. doi: 10.1155/2018/2068517. eCollection 2018. Sarcoma. 2018. PMID: 30473623 Free PMC article.

1. Choy E., Ballman K., Chen J., et al. SARC018_SPORE02: phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy. Sarcoma. 2018;2018:9. doi: 10.1155/2018/2068517.2068517 - DOI - PMC - PubMed